Sugi Predict

Sugi Predict / Compounds / Desmethylmoramide

Desmethylmoramide

Desmethylmoramide

SCHEMBL2111155

O=C(N1CCCC1)C(CCN1CCOCC1)(c1ccccc1)c1ccccc1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 4/20 0.68
▸ OPRD1 P41143 1/20 0.68
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ LMNA P02545 4/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ MAPT P10636 2/20 0.48
▸ CYP2D6 P10635 2/20 0.47
▸ CHRM2 P08172 1/20 0.47
▸ HTR1A P08908 1/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ HSP90AA1 P07900 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7744512 0.80 OPRM1 (0.66) OPRM1OPRD1SMN1; SMN2LMNAKMT2A
SCHEMBL6695001 0.79 OPRM1 (0.65) OPRM1OPRD1SMN1; SMN2LMNAKMT2A
SCHEMBL6662792 0.78 OPRM1 (0.55) OPRM1OPRD1SMN1; SMN2LMNAKMT2A
Hydrochloric Acid SCHEMBL7738855 0.78 OPRM1 (0.64) OPRM1OPRD1SMN1; SMN2LMNAKMT2A
SCHEMBL8603796 0.77 OPRM1 (0.58) OPRM1OPRD1
SCHEMBL6843620 0.77 OPRM1 (0.58) OPRM1OPRD1LMNAMAPTCYP2D6
Dioxaphetyl Butyrate SCHEMBL24240 0.77 OPRM1 (0.73) OPRM1OPRD1LMNACYP2C19KMT2A
SCHEMBL8740951 0.76 SMN1; SMN2 (0.66) OPRM1OPRD1SMN1; SMN2LMNACYP2C19
Dextromoramide SCHEMBL29395675 0.76 SMN1; SMN2 (0.51) OPRM1OPRD1SMN1; SMN2LMNACYP2C19
SCHEMBL6701358 0.76 OPRM1 (0.76) OPRM1OPRD1SMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
US-20260060822-A1 BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 — — US disclosed
US-12527770-B2 Methods of managing pain using dexmedetomidine transdermal delivery devices TEIKOKU PHARMA USA, INC. (US) 2026-01-20 — — US disclosed
US-20250366978-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF METHODIST HOSPITAL (US) 2025-12-04 — — US disclosed
US-20250366979-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF METHODIST HOSPITAL (US) 2025-12-04 — — US disclosed
US-20250251323-A1 COLLECTION PROBE AND METHODS OF USE THEREOF BAYLOR COLLEGE OF MEDICINE 2025-08-07 — — US disclosed
WO-2025128946-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF THE METHODIST HOSPITAL (US) 2025-06-19 — — WO disclosed
EP-4536139-A1 DEVICES AND METHODS OF MAKING AND USE THEREOF The Methodist Hospital (US) 2025-04-16 — — EP disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 — — US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 — — US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 — — US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 — — US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 — — US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 OPRM1 4114/4885OPRD1 4235/4885SMN1; SMN2 1551/4885
US-20260060822-A1 BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF PFKP, PBK, MYLK OPRM1 4810/4885OPRD1 4518/4885SMN1; SMN2 3109/4885
US-12527770-B2 Methods of managing pain using dexmedetomidine transdermal delivery devices OPRD1, OPRK1, OPRM1 OPRM1 3/4885OPRD1 1/4885SMN1; SMN2 958/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 OPRM1 4088/4885OPRD1 4225/4885SMN1; SMN2 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.